# US 10,872,102 B2 · Real time management of data relating to physiological control of glucose levels > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,872,102 B2 - Document ID: US10872102B2 - Status: Granted - Kind: B2 - Application number: 14/449,691 - Filed: 2014-08-01 - Published: 2014-11-20 - Granted: 2020-12-22 - Earliest claimed: 2009-07-23 - Assignees: Abbott Diabetes Care Inc. - Applicants: Abbott Diabetes Care Inc. - Inventors: Charles Wei; Gary Alan Hayter - Web page: https://patentgrep.com/patent/US10872102B2 ## CPC - G06F 16/285: {Clustering or classification} - A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement} - A61B 5/746: {Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms} - A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure} - G16H 20/30: relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising - G16H 40/60: for the operation of medical equipment or devices - G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems - G16H 50/30: for calculating health indices; for individual health risk assessment - G16H 50/50: for simulation or modelling of medical disorders - A61M 2005/14208: {with a programmable infusion control system, characterised by the infusion program} - A61M 2205/3592: using telemetric means, e.g. radio or optical transmission - A61M 2205/52: with memories providing a history of measured variating parameters of apparatus or patient - A61M 2230/201: Glucose concentration - G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N) - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA ## Abstract Continuous glucose monitoring (CGM) data and insulin delivery data are used to generate more reliable projected alarms related to a projected glucose levels. A memory stores endogenous data related to measurements of glucose level in a patient, and also stores exogenous data, such as insulin on board, both of which are used by a processor to create projected alarms. Profiles of CGM data are created for use in tuning patient-specific insulin data, such at basal rate, carb ratio, and insulin sensitivity. A processor searches for patterns in the data profiles and if found, recommended changes to patient-specific insulin data are provided to permit more accurate control over a patient's glucose levels. ## Claims ### Claim 1 An integrated glucose management system for treating diabetes of a patient, the system comprising: a controller comprising: a memory configured to store glucose measurement data wirelessly received from a continuous glucose monitoring sensor, and to store exogenous data including attributes tagged to the stored glucose measurement data; and a processor configured to execute computer-executable instructions to: automatically enable a profile recording feature to generate a first profile of a first profile type, the automatic enablement based on a first detected system-driven event; store glucose measurement data into the memory during a first defined time period to generate the first profile; automatically enable the profile recording feature to generate a plurality of subsequent profiles of subsequent profile types, the automatic enablement based on a plurality of subsequent detected system-driven events; store glucose measurement data into memory during a plurality of subsequent defined time periods to generate each of the plurality of subsequent profiles, wherein the first profile type and the subsequent profile types are selected from the group consisting of a skip-meal profile, a meal test profile, a correction bolus profile, a basal test profile, and an insulin action profile; tag one or more of the first profile and the plurality of subsequent profiles with an exogenous attribute; determine whether a persistent pattern of measured glucose levels exists among a minimum number of the first profile and the plurality of subsequent profiles of a same profile type, wherein the persistent pattern exists if the minimum number of the first profile and the plurality of subsequent profiles of the same profile type includes respective measured glucose levels outside of a glucose level target associated with the profile type; and output to a display a recommended change to medication data if the persistent pattern exists for a user to manage glucose levels within the glucose level target. ### Claim 2 (depends on 1) The integrated glucose management system of claim 1, wherein the medication data comprises one or more of a basal rate, a carb ratio, or an insulin sensitivity. ### Claim 3 (depends on 1) The integrated glucose management system of claim 1, wherein the processor comprises a computer-executable instruction to determine whether the persistent pattern exists among the minimum number of the first profile and the plurality of subsequent profiles of the same profile type within a selected time period. ### Claim 4 (depends on 1) The integrated glucose management system of claim 1, wherein the processor comprises a computer-executable instruction to determine that the recommended change to medication data does not exceed a predetermined amount, and wherein the medication data comprises one or more of a basal rate, a carb ratio, or an insulin sensitivity. ### Claim 5 (depends on 1) The integrated glucose management system of claim 1, wherein the exogenous attribute tag includes at least one of meal data, breakfast data, high-fat meal data, or post-prandial data. ### Claim 6 A method of treating diabetes, comprising: automatically enabling a profile recording feature to generate a first profile of a first profile type, the automatic enablement based on a first detected system-driven event; storing glucose measurement data received wirelessly from a continuous glucose monitoring sensor during a first defined time period to generate the first profile; automatically enabling the profile recording feature to generate a plurality of subsequent profiles of subsequent profile types, the automatic enablement based on plurality of subsequent detected system-driven events; storing glucose measurement data received wirelessly from the continuous glucose monitoring sensor during a plurality of subsequent defined time periods to generate the plurality of subsequent profiles, wherein the first profile type and the subsequent profile types are selected from the group consisting of a skip-meal profile, a meal test profile, a correction bolus profile, a basal test profile, and an insulin action profile; tagging one or more of the first profile and the plurality of subsequent profiles with an exogenous attribute; determining whether a persistent pattern of measured glucose levels exists among a minimum number of the first profile and the plurality of subsequent profiles of a same profile type, wherein the persistent pattern exists if the minimum number of the first profile and the plurality of subsequent profiles of the same profile type includes respective measured glucose levels outside of a glucose level target associated with the profile type; and outputting to a display a recommended change to medication data if the persistent pattern exists for a user to manage glucose levels within the glucose level target. ### Claim 7 (depends on 6) The method of claim 6, wherein the medication data comprises one or more of a basal rate, a carb ratio, or an insulin sensitivity. ### Claim 8 (depends on 6) The method of claim 6, wherein the minimum number of the first profile and the plurality of subsequent profiles of the same profile type are each within a selected time period for determining whether the persistent pattern exists. ### Claim 9 (depends on 6) The method of claim 6, further including determining that the recommended change to medication data does not exceed a predetermined amount, and wherein the medication data comprises one or more of a basal rate, a carb ratio, or an insulin sensitivity. ### Claim 10 (depends on 6) The method of claim 6, wherein the exogenous attribute tag includes at least one of meal data, breakfast data, high-fat meal data, or post-prandial data. ### Claim 11 (depends on 1) The integrated glucose management system of claim 1, wherein the processor comprises a computer-executable instructions to modify the medication data. ### Claim 12 (depends on 1) The integrated glucose management system of claim 1, further comprising a drug delivery device, wherein the drug delivery device is configured to deliver insulin based on the recommended change to the medication data. ### Claim 13 (depends on 6) The method of claim 6, further comprising modifying the medication data. ### Claim 14 (depends on 6) The method of claim 6, further comprising delivering insulin based on the recommended change to the medication data using a drug delivery device. ### Claim 15 (depends on 1) The integrated glucose management system of claim 1, wherein the processor comprises a computer-executable instruction to prioritize a recommended increase in carbohydrate intake lower than a recommended modification to medication delivery. ### Claim 16 (depends on 6) The method of claim 6, further comprising prioritizing a recommended increase in carbohydrate intake lower than a recommended modification to medication delivery. ### Claim 17 (depends on 1) The integrated glucose management system of claim 1, wherein the controller is in wireless communication with drug delivery device, and wherein the first detected system-driven event and the plurality of subsequent detected system-driven events are received from the drug delivery device. ### Claim 18 An integrated glucose management system for treating diabetes of a patient, the system comprising: a controller comprising: a memory configured to store glucose measurement data wirelessly received from a continuous glucose monitoring sensor, and to store exogenous data including attributes tagged to the stored glucose measurement data; and a processor configured to execute computer-executable instructions to: enable a profile recording feature to generate a first profile of a first profile type; store glucose measurement data into the memory during a first time period to generate the first profile; automatically end the profile recording feature after the first time period based on a first detected system-driven event; enable the profile recording feature to generate a plurality of subsequent profiles of subsequent profile types; store glucose measurement data into memory during a plurality of subsequent time periods to generate each of the plurality of subsequent profiles; automatically end the profile recording feature after the plurality of subsequent time periods based on a plurality of subsequent detected system-driven events, wherein the first profile type and the subsequent profile types are selected from the group consisting of a skip-meal profile, a meal test profile, a correction bolus profile, a basal test profile, and an insulin action profile; tag one or more of the first profile and the plurality of subsequent profiles with an exogenous attribute; determine whether a persistent pattern of measured glucose levels exists among a minimum number of the first profile and the plurality of subsequent profiles of a same profile type, wherein the persistent pattern exists if the minimum number of the first profile and the plurality of subsequent profiles of the same profile type includes respective measured glucose levels outside of a glucose level target associated with the profile type; and output to a display a recommended change to medication data if the persistent pattern exists for a user to manage glucose levels within the glucose level target. ### Claim 19 (depends on 18) The integrated glucose management system of claim 18, wherein the first detected system-driven event and the plurality of subsequent detected system-driven events are received from continuous glucose monitoring sensor. ### Claim 20 (depends on 18) The integrated glucose management system of claim 18, wherein the controller is in wireless communication with drug delivery device, and wherein the first detected system-driven event and the plurality of subsequent detected system-driven events are received from the drug delivery device.